Cargando…
Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease? Molnupiravir, a specific SARS-CoV-2 antiviral, may cause adverse genetic changes and thereby create potential host cell damage (through genotoxicit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309465/ https://www.ncbi.nlm.nih.gov/pubmed/35898799 http://dx.doi.org/10.1177/20420986221107753 |
_version_ | 1784753169017864192 |
---|---|
author | Clark, Nicole F. Taylor-Robinson, Andrew W. Heimann, Kirsten |
author_facet | Clark, Nicole F. Taylor-Robinson, Andrew W. Heimann, Kirsten |
author_sort | Clark, Nicole F. |
collection | PubMed |
description | Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease? Molnupiravir, a specific SARS-CoV-2 antiviral, may cause adverse genetic changes and thereby create potential host cell damage (through genotoxicity and DNA stressors). In our opinion, this side effect of treatment could be reduced if the antiviral was taken as a combined therapy with chlorophyllins. Specifically, we hypothesise that chlorophyllins might improve the overall effectiveness of molnupiravir, typically used to treat patients suffering from COVID-19. Chlorophyllins, antioxidants derived from natural plant chlorophyll, are safe, effective and non-toxic antioxidants that could combat possible genotoxic flow-on effects of molnupiravir. In addition, as they possess antiviral properties, treatment with chlorophyllins may enhance the overall antiviral effect via a mechanism different to molnupiravir. |
format | Online Article Text |
id | pubmed-9309465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-93094652022-07-26 Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir? Clark, Nicole F. Taylor-Robinson, Andrew W. Heimann, Kirsten Ther Adv Drug Saf Letter to the Editor Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease? Molnupiravir, a specific SARS-CoV-2 antiviral, may cause adverse genetic changes and thereby create potential host cell damage (through genotoxicity and DNA stressors). In our opinion, this side effect of treatment could be reduced if the antiviral was taken as a combined therapy with chlorophyllins. Specifically, we hypothesise that chlorophyllins might improve the overall effectiveness of molnupiravir, typically used to treat patients suffering from COVID-19. Chlorophyllins, antioxidants derived from natural plant chlorophyll, are safe, effective and non-toxic antioxidants that could combat possible genotoxic flow-on effects of molnupiravir. In addition, as they possess antiviral properties, treatment with chlorophyllins may enhance the overall antiviral effect via a mechanism different to molnupiravir. SAGE Publications 2022-07-21 /pmc/articles/PMC9309465/ /pubmed/35898799 http://dx.doi.org/10.1177/20420986221107753 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Letter to the Editor Clark, Nicole F. Taylor-Robinson, Andrew W. Heimann, Kirsten Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir? |
title | Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine
versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral
molnupiravir? |
title_full | Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine
versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral
molnupiravir? |
title_fullStr | Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine
versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral
molnupiravir? |
title_full_unstemmed | Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine
versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral
molnupiravir? |
title_short | Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine
versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral
molnupiravir? |
title_sort | could chlorophyllins improve the safety profile of beta-d-n4-hydroxycytidine
versus n-hydroxycytidine, the active ingredient of the sars-cov-2 antiviral
molnupiravir? |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309465/ https://www.ncbi.nlm.nih.gov/pubmed/35898799 http://dx.doi.org/10.1177/20420986221107753 |
work_keys_str_mv | AT clarknicolef couldchlorophyllinsimprovethesafetyprofileofbetadn4hydroxycytidineversusnhydroxycytidinetheactiveingredientofthesarscov2antiviralmolnupiravir AT taylorrobinsonandreww couldchlorophyllinsimprovethesafetyprofileofbetadn4hydroxycytidineversusnhydroxycytidinetheactiveingredientofthesarscov2antiviralmolnupiravir AT heimannkirsten couldchlorophyllinsimprovethesafetyprofileofbetadn4hydroxycytidineversusnhydroxycytidinetheactiveingredientofthesarscov2antiviralmolnupiravir |